You are not logged in.

Capecitabine and oral cyclophosphamide : a novel oral treatment combination for advanced cancer

Findlay, Michael, Sharples, Katrina, Riley, Greta A., Simpson, Andrew, Ackland, Stephen, Hall, Katherine, Isaacs, Richard, Humm, Gillian and McKeage, Mark J. 2007, Capecitabine and oral cyclophosphamide : a novel oral treatment combination for advanced cancer, Asia-Pacific journal of clinical oncology, vol. 3, no. 2, pp. 99-105, doi: 10.1111/j.1743-7563.2007.00095.x.

Attached Files
Name Description MIMEType Size Downloads

Title Capecitabine and oral cyclophosphamide : a novel oral treatment combination for advanced cancer
Author(s) Findlay, Michael
Sharples, Katrina
Riley, Greta A.
Simpson, Andrew
Ackland, Stephen
Hall, Katherine
Isaacs, Richard
Humm, Gillian
McKeage, Mark J.
Journal name Asia-Pacific journal of clinical oncology
Volume number 3
Issue number 2
Start page 99
End page 105
Total pages 7
Publisher Wiley-Blackwell Publishing
Place of publication Oxford, England
Publication date 2007
ISSN 1743-7555
Keyword(s) administration
anti-neoplastic combined chemotherapy protocol
clinical trial
phase I
Summary Background: This dose escalation study assessed feasibility of a totally oral chemotherapy regimen using cyclophosphamide and capecitabine. The rationale for this combination was based on the observation that preclinical models of cyclophosphamide up-regulated tumor thymidine phosphorylase and increased the activation of capecitabine. Methods: Eligible patients with advanced cancer were treated with oral cyclophosphamide and capecitabine on a 28-day cycle. If no dose limiting toxicities (DLT) were encountered during the first two treatment cycles, the next patient group was assigned to the next highest dose level until the maximum tolerable dose (MTD) was determined. Results: Twenty-seven patients entered treatment. The majority of non-DLT were grades 1 and 2. DLT experienced in the first 8-week observation period were grade 3 diarrhea (one patient, level III) and grade 3 emesis (two patients, level V). MTD was observed at level 5, 1331 mg/m2/day capecitabine days 1–28 with 125 mg/m2/day cyclophosphamide days 1–14 of the 28-day cycle. The recommended phase II dose is therefore 1331 mg/m2/day capecitabine with 100 mg/m2/day cyclophosphamide. The best response evaluation showed four partial responses (breast, colon, ovary and pancreas). Conclusion: Cyclophosphamide and capecitabine can be combined at their full oral single agent dose with promising tolerability and activity.
Language eng
DOI 10.1111/j.1743-7563.2007.00095.x
Field of Research 179999 Psychology and Cognitive Sciences not elsewhere classified
Socio Economic Objective 970117 Expanding Knowledge in Psychology and Cognitive Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Persistent URL

Document type: Journal Article
Collection: School of Psychology
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in TR Web of Science
Scopus Citation Count Cited 5 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 176 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Tue, 07 May 2013, 14:05:02 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact